미국의 전기 요법 시장 규모, 점유율 및 동향 분석 보고서 : 치료법별, 용도별 및 부문 예측(2025-2033년)

U.S. Electrotherapy Market Summary

The U.S. electrotherapy market size was estimated at USD 480.31 million in 2024 and is anticipated to reach USD 693.90 million by 2033, expanding at a CAGR of 4.24% from 2025 to 2033. This growth is attributed to the growing prevalence of chronic pain, musculoskeletal disorders, and sports-related injuries, which have increased the demand for non-invasive and drug-free pain management solutions.

The aging population, which is more prone to arthritis, neuropathy, and post-surgical pain, further fuels market growth. In addition, advancements in technology, such as portable, wearable, and smart electrotherapy devices integrated with digital monitoring, are enhancing treatment efficacy and patient convenience. The rising preference for home healthcare and rehabilitation therapies, combined with the shift away from opioid-based pain management, continues to strengthen the adoption of electrotherapy devices across clinical and home settings in the U.S.

Another key growth driver in the U.S. market is the rapidly aging population, which is highly susceptible to conditions such as arthritis, neuropathy, and post-stroke mobility limitations. The U.S. Census Bureau projects that by 2035, older adults (aged 65 and above) will outnumber children for the first time in U.S. history, creating a substantial patient base requiring long-term pain and muscle management therapies. Electrotherapy is increasingly being adopted in geriatric care to improve muscle function, circulation, and overall mobility, thereby enhancing quality of life. Moreover, the ongoing opioid crisis in the U.S. has strengthened the focus on non-opioid pain management solutions. Federal initiatives, such as the CDC's guidelines promoting non-pharmacological treatments for chronic pain, have further encouraged physicians and patients to opt for electrotherapy as a safer, non-addictive alternative.

The growing shift toward non-invasive and drug-free pain management therapies is a significant factor driving the U.S. electrotherapy device market. With the nation grappling with an ongoing opioid crisis, both healthcare providers and patients are increasingly seeking safer alternatives to traditional pain medications. Electrotherapy offers effective, localized pain relief without the risk of addiction, dependency, or systemic side effects associated with opioids. Federal initiatives, such as the Centers for Disease Control and Prevention (CDC) guidelines promoting non-pharmacological approaches for chronic pain, have further accelerated the adoption of electrotherapy devices across hospitals, rehabilitation centers, and home care settings. As awareness of opioid-related risks continues to rise, the demand for electrotherapy devices, such as Transcutaneous Electrical Nerve Stimulation (TENS) and Neuromuscular Electrical Stimulation (NMES) systems, is expected to grow significantly, supporting the broader shift toward safer, technology-driven pain management solutions in the U.S. healthcare landscape.

The growing awareness and adoption of rehabilitation therapies indirectly drive the U.S. electrosurgery market by enhancing the overall continuum of care following surgical procedures. As more patients and clinicians recognize the importance of post-surgical rehabilitation for faster recovery and improved functional outcomes, the demand for minimally invasive surgical techniques, including those performed with electrosurgical devices, is increasing. Electrosurgery enables precise tissue cutting, coagulation, and hemostasis with minimal thermal damage, which helps reduce surgical trauma and accelerates postoperative recovery, allowing patients to begin rehabilitation sooner. This alignment between advanced surgical methods and rehabilitation-focused treatment pathways encourages hospitals and surgical centers to adopt modern electrosurgical systems that support quicker healing, fewer complications, and improved patient mobility, ultimately fueling market growth in the U.S.

U.S. Electrotherapy Market Report Segmentation

This report forecasts revenue growth at the country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For the purpose of this study, Grand View Research has segmented the U.S. electrotherapy market report on the basis of therapy type and application:

• Therapy Type Outlook (Revenue, USD Million, 2021 - 2033)
• Transcutaneous Electrical Nerve Stimulation (TENS)
• Interferential Therapy (IFT)
• NMES/FES
• Others
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Nervous Disease
• Muscle Injury
• Inflammation
• Pain Relief
• Others

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Therapy Type
  • 1.1.2. Application
  • 1.1.3. Estimates And Forecast Timeline
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased Database
  • 1.3.2. GVR's Internal Database
  • 1.3.3. Secondary Sources
  • 1.3.4. Primary Research
  • 1.3.5. Details Of Primary Research
• 1.4. Information or Data Analysis
  • 1.4.1. Data Analysis Models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity Price Analysis (Model 1)
  • 1.6.2. Approach 1: Commodity Flow Approach
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Electrotherapy Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Rising prevalence of chronic pain and musculoskeletal disorders
    • 3.2.1.2. Increasing geriatric population
    • 3.2.1.3. Growing adoption of non-invasive and drug-free pain management therapies
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High cost of advanced electrotherapy devices
    • 3.2.2.2. Limited clinical evidence and skepticism among healthcare professionals
  • 3.2.3. Market Opportunity Analysis
    • 3.2.3.1. Integration of AI and IoT in electrotherapy devices
    • 3.2.3.2. Rising demand in home-based rehabilitation and telehealth settings
  • 3.2.4. Market Challenge Analysis
    • 3.2.4.1. Stringent quality and safety standards
• 3.3. U.S. Electrotherapy Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's Five Forces
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. U.S. Electrotherapy Market: Therapy Type Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. U.S. Electrotherapy Market Therapy Type Movement Analysis
• 4.3. U.S. Electrotherapy Market Size & Trend Analysis, by Therapy Type 2021 to 2033 (USD Million)
• 4.4. Transcutaneous Electrical Nerve Stimulation (TENS)
  • 4.4.1. Transcutaneous Electrical Nerve Stimulation (TENS) Market Estimates and Forecasts for 2021 to 2033 (USD Million)
• 4.5. Interferential Therapy (IFT)
  • 4.5.1. Interferential Therapy (IFT) Market Estimates and Forecasts for 2021 to 2033 (USD Million)
• 4.6. NMES/FES
  • 4.6.1. NMES/FES Market Estimates and Forecasts for 2021 to 2033 (USD Million)
• 4.7. Others
  • 4.7.1. Others Market Estimates and Forecasts for 2021 to 2033 (USD Million)

Chapter 5. U.S. Electrotherapy Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. U.S. Electrotherapy Market Application Movement Analysis
• 5.3. U.S. Electrotherapy Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
• 5.4. Nervous Disease
  • 5.4.1. Nervous Disease Market Estimates and Forecasts for 2021 to 2033 (USD Million)
• 5.5. Muscle Injury
  • 5.5.1. Muscle Injury Market Estimates and Forecasts for 2021 to 2033 (USD Million)
• 5.6. Inflammation
  • 5.6.1. Inflammation Market Estimates and Forecasts for 2021 to 2033 (USD Million)
• 5.7. Pain Relief
  • 5.7.1. Pain Relief Market Estimates and Forecasts for 2021 to 2033 (USD Million)
• 5.8. Others
  • 5.8.1. Others Market Estimates and Forecasts for 2021 to 2033 (USD Million)

Chapter 6. Competitive Landscape

• 6.1. Recent Developments & Impact Analysis, By Key Market Participants
• 6.2. Company/Competition Categorization
  • 6.2.1. Innovators
• 6.3. Vendor Landscape
  • 6.3.1. Key company market share analysis, 2024
  • 6.3.2. Zynex Medical
    • 6.3.2.1. Company overview
    • 6.3.2.2. Financial performance
    • 6.3.2.3. Usage benchmarking
    • 6.3.2.4. Strategic initiatives
  • 6.3.3. BTL Group of Companies
    • 6.3.3.1. Company overview
    • 6.3.3.2. Financial performance
    • 6.3.3.3. Usage benchmarking
    • 6.3.3.4. Strategic initiatives
  • 6.3.4. Omron Healthcare, Inc.
    • 6.3.4.1. Company overview
    • 6.3.4.2. Financial performance
    • 6.3.4.3. Usage benchmarking
    • 6.3.4.4. Strategic initiatives
  • 6.3.5. NeuroMetrix, Inc.
    • 6.3.5.1. Company overview
    • 6.3.5.2. Financial performance
    • 6.3.5.3. Usage benchmarking
    • 6.3.5.4. Strategic initiatives
  • 6.3.6. GymnaUniphy
    • 6.3.6.1. Company overview
    • 6.3.6.2. Financial performance
    • 6.3.6.3. Usage benchmarking
    • 6.3.6.4. Strategic initiatives
  • 6.3.7. Enovis Corporation
    • 6.3.7.1. Company overview
    • 6.3.7.2. Financial performance
    • 6.3.7.3. Usage benchmarking
    • 6.3.7.4. Strategic initiatives
  • 6.3.8. Medtronic
    • 6.3.8.1. Company overview
    • 6.3.8.2. Financial performance
    • 6.3.8.3. Usage benchmarking
    • 6.3.8.4. Strategic initiatives
  • 6.3.9. Omron Healthcare, Inc.
    • 6.3.9.1. Company overview
    • 6.3.9.2. Financial performance
    • 6.3.9.3. Usage benchmarking
    • 6.3.9.4. Strategic initiatives
  • 6.3.10. Dentis Co., Ltd.
    • 6.3.10.1. Company overview
    • 6.3.10.2. Financial performance
    • 6.3.10.3. Usage benchmarking
    • 6.3.10.4. Strategic initiatives
  • 6.3.11. Stymco
    • 6.3.11.1. Company overview
    • 6.3.11.2. Financial performance
    • 6.3.11.3. Usage benchmarking
    • 6.3.11.4. Strategic initiatives
  • 6.3.12. RS Medical
    • 6.3.12.1. Company overview
    • 6.3.12.2. Financial performance
    • 6.3.12.3. Usage benchmarking
    • 6.3.12.4. Strategic initiatives
  • 6.3.13. Orthofix Medical
    • 6.3.13.1. Company overview
    • 6.3.13.2. Financial performance
    • 6.3.13.3. Usage benchmarking
    • 6.3.13.4. Strategic initiatives